Predictive Biomarkers and Personalized Medicine

## Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Elena Garralda<sup>1</sup>, Keren Paz<sup>4</sup>, Pedro P. López-Casas<sup>1</sup>, Siân Jones<sup>5</sup>, Amanda Katz<sup>4</sup>, Lisa M. Kann<sup>5</sup>, Fernando López-Rios<sup>2</sup>, Francesca Sarno<sup>3</sup>, Fátima Al-Shahrour<sup>1</sup>, David Vasquez<sup>4</sup>, Elizabeth Bruckheimer<sup>4</sup>, Samuel V. Angiuoli<sup>5</sup>, Antonio Calles<sup>1</sup>, Luis A. Diaz<sup>6</sup>, Victor E. Velculescu<sup>6</sup>, Alfonso Valencia<sup>1</sup>, David Sidransky<sup>4</sup>, and Manuel Hidalgo<sup>1</sup>

#### Abstract

**Background:** Current technology permits an unbiased massive analysis of somatic genetic alterations from tumor DNA as well as the generation of individualized mouse xenografts (Avatar models). This work aimed to evaluate our experience integrating these two strategies to personalize the treatment of patients with cancer.

**Methods:** We performed whole-exome sequencing analysis of 25 patients with advanced solid tumors to identify putatively actionable tumor-specific genomic alterations. Avatar models were used as an *in vivo* platform to test proposed treatment strategies.

**Results:** Successful exome sequencing analyses have been obtained for 23 patients. Tumor-specific mutations and copy-number variations were identified. All samples profiled contained relevant genomic alterations. Tumor was implanted to create an Avatar model from 14 patients and 10 succeeded. Occasionally, actionable alterations such as mutations in *NF1*, *PI3KA*, and *DDR2* failed to provide any benefit when a targeted drug was tested in the Avatar and, accordingly, treatment of the patients with these drugs was not effective. To date, 13 patients have received a personalized treatment and 6 achieved durable partial remissions. Prior testing of candidate treatments in Avatar models correlated with clinical response and helped to select empirical treatments in some patients with no actionable mutations.

**Conclusion:** The use of full genomic analysis for cancer care is encouraging but presents important challenges that will need to be solved for broad clinical application. Avatar models are a promising investigational platform for therapeutic decision making. While limitations still exist, this strategy should be further tested. *Clin Cancer Res; 20(9); 2476–84.* ©2014 AACR.

## Introduction

Cancer is considered a disease caused and driven by the accumulation of genetic aberrations (1). Virtually every cancer has its unique set of molecular changes, and the knowledge of such alterations in the clinical arena could ultimately facilitate an individualized approach to cancer treatment (2, 3). Recent advances in timeliness and cost of next-generation sequencing (NGS) technologies allow for

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

**Corresponding Author:** Manuel Hidalgo, Centro Nacional de Investigaciones Oncológicas (CNIO; Spanish National Cancer Research Centre), Melchor Fernández Almagro n° 3, E-28029 Madrid, Spain. Phone: 349-1732-8000, ext. 2920; Fax: 349-1536-0432; E-mail: mhidalgo@cnio.es

doi: 10.1158/1078-0432.CCR-13-3047

©2014 American Association for Cancer Research.

the characterization of the cancer genome in a time frame that is compatible with treatment decisions, offering the opportunity to potentially increase the therapeutic efficacy by targeting the genomic aberrations driving tumor behavior (4-6).

There are, however, still significant challenges to integrate genomic testing into cancer treatment decision-making as the interpretation of the genomic information is still defying. On the one end, for most cancers there are a large number of mutations considered to be relevant (7, 8). While many of those are not drug targets, it is common to find several potential treatment opportunities for each given patient. How to prioritize these potential treatments is an unresolved issue (9). At present, the ability to generate genomic data supersedes the capacity to draw inferences from prior experiences and make informed treatment recommendations that can benefit the profiled individual patient. Novel tools to integrate genomic information with traditional clinical and pathologic data in an iterative manner are still needed (10). Here, we present our experience using a combined approach of exome sequencing and personalized xenografting to define patient therapy. A key component of our approach is the development of patientderived xenografts, so-called Avatar mouse models, that

2476 Clin Cancer Res; 20(9) May 1, 2014

Authors' Affiliations: <sup>1</sup>Spanish National Cancer Research Centre (CNIO), Madrid, Spain; <sup>2</sup>Champions Oncology, Baltimore, Maryland; <sup>3</sup>Personal Genome Diagnostics, Inc., Baltimore, Maryland; <sup>4</sup>Laboratorio Dianas Terapéuticas, Hospital Universitario Madrid-Sanchinarro, Madrid, Spain; <sup>5</sup>Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid-Sanchinarro, Madrid, Spain; <sup>6</sup>Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland

## **Translational Relevance**

Despite the clear potential of tailoring cancer treatment using genomics data and the appearance of exciting technological advances, a plethora of challenges remain to be resolved before wide-spread implementation of personalized therapy. The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient outcomes. Personalized xenografts developed in mice from patients' tumor tissues could aid in the process of interpreting genomic analyses, identifying actionable leads, and relating these to the drug space. This work describes one of the first experiences to apply exome sequencing and patient-derived xenografts, so-called Avatar mouse models, to personalizing cancer treatment in the clinic in real time. This approach is of clear interest as a means to better define optimal therapy for patients with advanced cancers.

permits bench testing of treatment strategies derived from the genomic analysis (11, 12).

### **Materials and Methods**

This is a retrospective analysis of the patients that have received in our centers a personalized treatment approach

tailored by the integration of exome sequencing and Avatar mouse models during the past 4 years. It represents a proofof-concept case report as it demonstrates the feasibility of combining both technologies in the clinical setting and guide individual patient treatment. The protocol was Institutional Review Board approved and all patients signed informed consent.

#### Overview of personalized treatment approach

Patients had an exome characterization of tumor and normal tissue and bioinformatic analysis to determine the most biologically relevant somatic mutations. Simultaneously, we attempted to generate an Avatar mouse model from the same patient. Using genomic analysis, we integrated this information to help manually select a group of 5 to 10 treatments, which were then bench tested in the Avatar mouse model to select the most effective treatment candidate for the patient. Figure 1 shows a study schema.

### **Patient eligibility**

All patients were adults with noncurable advanced cancer with an Eastern Cooperative Oncology Group (ECOG) performance status 0–1 and adequate bone marrow, liver, and renal function to receive chemotherapy. Either archival tumor tissue (preferentially frozen), xenograft tissue from the patient's tumor, or tumor lesions suitable for a tumor biopsy were used.



Figure 1. Study design schema.

www.aacrjournals.org

## Genomic and bioinformatics analysis

After pathologic review, thin sections were obtained for specialized dissection and purification of the tumor DNA to enrich for tumor purity. Tumor formalin-fixed paraffinembedded blocks were cut in 3 µm thick sections, stained with hematoxylin and eosin, and assessed by a pathologist to confirm tumor type and mark regions predominantly containing neoplasic cells and normal tissue. An adjusted number of consecutive unstained slides of 8 to 10 µm thickness were used for macro-dissection in each case to yield approximately 250 ng of DNA. DNA samples were enriched for coding regions in the genome using custom DNA capture approaches. Matching normal DNA was obtained from blood. Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina). Exonic regions were captured in solution using the Agilent SureSelect 51 Mb Kit (version 4) according to the manufacturer's instructions (Agilent). These include the coding exons of ~20,000 genes covering >50 Mb of the genome. Paired-end sequencing, resulting in 100 bases from each end of the fragments, was performed using a HiSeq 2000 Genome Analyzer (Illumina). Exome sequencing was performed at depths of  $75 \times$  to  $>200 \times$  depending on the tumor purity. The tags were aligned to the human genome reference sequence (hg18) using the Eland algorithm of CASAVA 1.7 software (Illumina). The chastity filter of the BaseCall software of Illumina was used to select sequence reads for subsequent analysis. The ELAND algorithm of CASAVA 1.7 software (Illumina) was then applied to identify point mutations and small insertions and deletions.

The resulting alterations are compared among tumor and normal sequence data as well as to databases of known variants to distinguish common variants, private (rare) germline changes, and potential somatic alterations. Known polymorphisms recorded in dbSNP were removed from the analysis. Potential somatic mutations were filtered and visually inspected. We used three *in silico* methods (Polyphen, SIFT, SNP&GO) to estimate the functional significance of a given confirmed mutation.

## Generation of Avatar mouse models

We attempted to establish an Avatar model from each of the patients following the methodology previously published by our group (12, 13). Mice used in this research have been treated humanely according to the regulations laid down by the Bioethics Committee and the relevant EC guidelines (directive 86/609/EEC), with due consideration to the alleviation of distress and discomfort. More detailed information about the Avatar generation protocols can be found in the Supplementary Material. Briefly, a tumor specimen obtained by a tumor biopsy was transplanted and propagated in nude mice. Avatar models were mostly generated by specimens obtained from fresh biopsies of metastasis, as they were generally more accessible than the primary tumors and generally represent a more advanced tumor clone with additional driver/aggressive mutations. Once the tumor specimen was in an exponential growth phase, cohorts of mice with tumor sizes of 0.15 to 0.3 mL were randomized to several treatment groups. The xenograft provided a mechanism to test for the most effective agent if there were several candidate agents identified with exome sequencing and to formulate treatment recommendations for patients in whom the genomic analysis was not contributory.

## Patient treatments and follow-up

The patients included in the study started receiving conventional treatment while exome sequencing and Avatar models were being generated and tested. Those that afterwards presented with progressive disease received the personalized treatment accordingly to the results.

A team integrated by biologists, clinicians, and bioinformaticians performed the decision-making process of choosing the most appropriate molecular treatment for the Avatars, and the most "actionable" Avatar-suggested treatment for the patients. This was performed by (i) the prioritization of candidate driver mutations, (ii) the interpretation of the mutations at the pathway/metabolic level, and (iii) selecting the drugs potentially related with those pathways and processes.

Patients were treated with either standard-of-care regimens or referred to clinical trials with new drugs. Several medical and technical issues influenced the use of standard or personalized treatments approach such as the finding or not of a druggable target, the viability of obtaining a specific treatment, and the timing and condition of the patients when the data were available. Treatments administration, toxicity monitoring, and management and efficacy assessment were performed as per current practice guidelines or as specified in the research protocols.

## Results

## **General results**

A total of 25 patients were included. Table 1 summarizes the most relevant clinical characteristics of these patients. Successful exome sequencing analyses were obtained for 23 patients. Two patients with pancreatic cancer progressed rapidly and the procedures were aborted. An Avatar mouse model was successfully generated in 10 of 14 patients. In 9 patients, a model could not be generated due to either technical reasons or patient refusal. A total of 13 patients received a cancer treatment based on the genomic and/or Avatar mouse model data to date. Three additional patients are still in response with up front chemotherapy and will be treated at the time of progression with a personalized regimen. The remaining 7 patients have not received a personalize therapy because of failure to find a suitable druggable alteration (2 cases), poor performance status that precluded patient treatment (1 case), or lack of access to investigational agents (4 cases).

## Genomic analysis

More than 30 million bases of target DNA were analyzed in the tumor and normal samples in every case, with an average of at least 70 distinct reads at each base. Supplementary Table S1 lists, for each one of these patients, tumor-specific mutations and copy-number variations (CNV) as determined by bioinformatics analysis. For each patient, the mutated genes symbol, gene description, functional group and pathway, transcript accession, mutation position, the genomic, transcript and protein level, and the mutation type is listed.

The number of somatic mutations and CNVs ranged from 5 to 952 and from 0 to 965, respectively. The median number of mutations was 45 and median CNV was 6. From this list of candidates, we manually extracted the most relevant alterations and from this, the clinical actionable genetic alterations that could be targeted with current drug armamentarium. As shown in Table 2, these results varied significantly from one patient to another with patients such as patient #1 with a low grade intestinal neuroendocrine tumor having only one targetable mutation in *CREB3L3* and patient #7 with malignant melanoma with mutations in more than 10 well accepted drug targets such as *IGF1R*, *MET*, *PI3K*, and *FGFR*.

Characteristics	Number of patients (%
Sex	
Male	15 (60)
Female	10 (40)
Age, y	
Median	55
Range	35–74
Number of prior treatment regimens	
Median	3
Range	1–8
Primary tumor type	
Colorectal	3 (12)
Glioblastoma	2 (8)
Pancreas	7 (28)
NSCLC	5 (20)
Melanoma	3 (12)
Other <sup>a</sup>	5 (20)
Attempted Avatar generation	14 (61)
Engraftment success	10 (71)
Successful exome sequencing obtained	23 (92)
Successful CNV obtained	21 (84)
Received personalized treatment	13 (57)
Not received personalized treatment	12 (43)
On standard first-line treatment	3 (30)
Not suitable druggable alteration	2 (20)
Poor performance status	3 (10)
Difficult access to drug	4 (40)

## Avatar mouse models

To empirically test the tumor response to theoretical treatments and make individual patient treatment decisions, we generated Avatar mouse models from 14 of these patients. Supplementary Table S2 lists the specific regimens, dosing details, and responses observed in the Avatar.

The Avatar models proved valuable to help interpret the genomic information. This is well illustrated in patient #3. Genomic analysis of this patient showed 62 somatic mutations and 6 CNV. Exome sequencing detected the p.F909C mutation in the catalytic domain of the phosphoinositide 3kinase protein, leading to a volume change (from bulky F to a smaller C) with the introduction of possible S-S bonds. The severity of this mutation was estimated to be high based on structural information (Fig. 2A), and two other mutations involving PI3KCA F909 were reported by the Cosmic database (p.F909L and F909S). Furthermore, the presence of GNG11 amplification suggested activation of the Ras-Raf-MEK pathway in this tumor with wild-type RAS and RAF genes (14). To evaluate these therapeutic options, we treated the patient Avatar model. As shown in Fig. 1C, treatment with a PI3K inhibitor alone did not show evidence of tumor control and indeed there was no evidence of activation of the PI3K pathway in this tumor despite the presence of a PI3K mutation (Fig. 2B). Interestingly, the use of the Avatar model enabled a more complete analysis, testing drug cocktails, and showed the combination of a PI3K and MEK inhibitors as a possible effective approach (Fig. 2C). Unfortunately, we did not find access to such a combination in the clinic to offer the patient. Gemcitabine was also effective, but the patient had already failed this treatment previously as he had initially been diagnosed as a pancreatic adenocarcinoma in another center. In addition, this tumor also had a somatic mutation of discoidin domain receptor 2 (DDR2), which had been just recently reported to be associated with increased sensitivity to dasatinib (15). The patient was started on dasatinib, as due to time restrains we could not wait to obtain the Avatar results. In both the patient and the xenograft, treatment failed. (Fig. 2D).

Likewise, the glioblastoma of patient #2 had 63 mutations and 23 CNVs detected including a mutation in Neurofibromin 1 (*NF1*). Inactivation of *NF1* gene has been related to an increased activity of downstream RAS pathways which was demonstrated in this case (Fig. 2B). As hyperactivation of RAS turns signals through the RAF/MEK/ ERK and PI3K/mTOR pathways to regulate cell growth and survival (16, 17), a battery of treatments, including PI3K and MEK inhibitors, were tested (Fig. 2E and F). The most effective treatment in the Avatar model was the combination of everolimus and erlotinib (reported to be effective in low-grade gliomas with NF1 inactivation (16) that slowed tumor growth but did not result in tumor shrinkage. Patient treatment was stopped 3 months later due to lack of clinical benefit without clear radiologic progressive disease.

Avatar models also proved useful for a direct assessment between potential targeted therapies based on genomic information and potentially active chemotherapy regimens selected from a long list of phase II studies. This is well seen

www.aacrjournals.org

FLODFLODControlCControlCCCCFLODFLODFLODFDOFDOFDOFDOFDOFDOFDOFDOFLODFLODFLODFDOFDOFDOFDOFDOFDOFDOFDOFLODFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDOFDOFDOFDOFLODFDOFDOFDOFDOFDOFDOFDO	≝ _	Patient Id	Neuroendocrine	N# Mutations	Relevant somatic mutations			CEER21 2
PCDXXFCDXXColColNotNotNotPCDXXGlobble pareneticatione function23 $FPDAAA NFP, FTPAU1, FAS, CDX0AA$ 00Not foundPCDXTPareneticatione function33 $STFRZ, DANDAX, SANDAAA$ 100Not foundPCDX1Pareneticatione function33 $STFRZ, DANDAX, SANDAAA$ 100Not foundPCDX13Pareneticatione function5 $OAUT, FADAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA$		PGUX4	Neuroenaocrine tumor	n	CREBSLS, ILPAZ, MYOOB	Þ	Þ	CHEBSLS
PGDXHigh grade partoratic anomotione turnorAdditional Process astres_ DDR2_PressAdditional Press astres_ DDR2_PressAdditional Press 		PGDX30	Glioblastoma	63	EPHA3, NF1, PTPN11, FAS, CDKN2A	0	0	NF1
Internendorine fundAVAIIR2: AVAIG2: A, FM3CA,		PGDX7	High grade pancreatic	62	ARID1A, ARID1B,	9	GNG11	PI3KCA, DDR2
FCDX11Parcentic38 <i>Keñá: Ubát, É Mis34; SM/D4, SLC15A2, PML3.</i> 1000Met foundPCDX81Adenocarior5 $GAV1, FAR3. CZ2417, FR33.$ 00 </td <td></td> <td></td> <td>neuroendocrine tumor</td> <td></td> <td>JAKMIP2, JARID2, PIK3C2A, PIK3CA, SSTR2 DDR2 TP53</td> <td></td> <td></td> <td></td>			neuroendocrine tumor		JAKMIP2, JARID2, PIK3C2A, PIK3CA, SSTR2 DDR2 TP53			
AdenocarcinomAdenocarcinomaccost st.czs.it.7accost st.czs.		PGDX11	Pancreatic	38	KBAS, UBA1, FAM83H, SMAD4, SLC15A2, PIWIL3.	10	0	Not found
PEDNBIPEDNBI5 $OM11, TAOR3$ $OH11, TAOR3$ $OH11, TAOR3$ $OH11, TAOR3$ $OH11, TAOR3$ $OH11, TAOR3, CHC1, SOT1OH11, TAOR3, CHC1, SOT1OH11, TAOR3, CHC1, SOT1OH11, TAOR3, CHC1, SOT1OH11, TAOS3, CHC1, SOT1OH11, TAO33, CHC1, SOT1, SOT1, TAO33, CHC1, SOT1OH11, TAO33, CHC1, SOT1, SOT1, TAO33, CHC1, SOT1OH11, TAO33, CHC1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, SOT1, TAO33, CHC1, SOT1, SOT1, SOT1, SOT1, SOT1, TAO33, CHC1, SOT1, TAO33, CHC1, SOT1, $			Adenocarcinoma	1	SLC3A2, SLC22A17, TP53		I	
PGDN68Contraction71ACC DCENT, TyrS, CHENT, SOS1630CHENT, SOS1PGDX05Melanoma92 $RGAI, KET, REP, RAN, RAGE, R$		PGDX61	Melanoma Uveal	5	GNA11, TAOK3	0	0	GNA11
FEDX76Meanone92BRCJI, EZH, EFH, MET, RFL, MI, GFTR, KUR,00GFR2, IGFTR, MET, RFL, MET, MET, RFL,		PGDX68	Colon cancer	71	APC, DICER 1, TP53, CHEK1, SOS1	63	0	CHEK1
PERCALPERCACAPERCACAPERCACAPERCACAPOLYC81Parceatic18 $RAAJA, RAS, FAB22P$ 02 $S, RT19$ NexC2G, MET, BFCA1Adenocarcitoma21 $RAAJA, RAS, FAB22P$ 000REB2PNexC2G, MET, BFCA1Adenocarcitoma21 $RAAS, PC, PS3$ $SAAAA, RAS, FAB22P$ 000XeCAdenocarcitoma23 $RAS, PC, PS3$ $RAAS, PS3, SAAAA300XeCAdenocarcitoma26RAS, PC3, SAAAA300Not toutedAdenocarcitoma25BA71RAS, PC3, RAAA30Not toutedAdenocarcitoma26RAS, PC3, SAAAA300Not toutedAdenocarcitoma26BA71RA3, PS3, RAD430Not toutedAdenocarcitoma26BA71RA3, PS3, RAD430Not toutedAdenocarcitoma64MLT0, PBHM127RR3, RAT1, RAA1Not CH1, RAA1Adenocarcitoma64RA3, RA7, RAS, RAA730PC0RA1Adenocarcitoma64RA3, RA7, RAS, RAA730PC0RA1Adenocarcitoma64RA3, RA7, RAS, RAA73CD0RA2A, RAB71Adenocarcitoma7RC1C390PC0RA1Adenocarcitoma64RA1, RAS, RA471, RAS, RAA71, RAS,$		PGDX76	Melanoma	952	BRCA1, EZH2, FGFR2, FN1, IGF1R, KDR,	0	0	FGFR2, IGF1R,
PGDX135Parcentic Admonzationma20BAJ3. DWAH6, MON1, MASS2SKT19NBSPGDX351Parcentic Admonzationma21 $SMAD4, KPAS, EPBE2P$ 000EBB22PAdmonzationma21 $KAAS, XPC, PS3MAD4, KPAS, EPBE2P000XPCAdmonzationma21KAAS, XPC, PS3MAD430Not foundNot controlAdmonzationma29KAAS, PS3, SMAD430Not foundNot controlNot controlAdmonzationma29KAAS, PS3, SMAD430Not foundNot controlNot controlAdmonzationma29KAAS, PS3, SMAD430Not controlNot controlNot control2PGDX3712Reral Carcinoma25BAP1NAT70, PBM11STA71, GM11, SM11, SM1$					KRAS, MET, MPL, PRKCB, PIK3C2G, PTK2B			PIK3C2G, MET, BRCA1
PGDX368Panceatic18 $SMAD4, KPA, ERB2/P$ 000EBB2/P0PABrocationa21 $KPA, FC, F33$ 000XPC1PABrocationa21 $KPA, FS, SMAD4$ 300XPC1Panceati29 $KRA, FS, SMAD4$ 300Notout2Panceationa25 $BAP1, FGFR3$ $NPT, FGFR3$ $NPT, FGFR3$ $NPT, FGFR3$ 2PEDX37912Peal Carcinona25 $BAP1, FGFR4$ $NOTCH1, TEFR1$ $NOTCH1, FBFR1$ $NOTCH1, SRV1, GMA11$ 2PEDX27S10S100 bastoma25 $BAP1, FGFR3$ $NPT, FGFR3$ $NOTCH1, FBFR1$ $NOTCH1, SRV1, GMA11$ 2PEDX27S10S10S10 $S10, S10, S10, S10, S10, S10, S10, S10, $		PGDX135	Melanoma	29	BAI3, DNAH5, MDN1, NRAS	2	SKT19	NRAS
Inderstand Altenocarcitoma21KRAS, KPC, FS300NN1PGDX369Pancreatic29KRAS, FS3, SMAD430Not found2Adenocarcitoma29KRAS, FS3, SMAD430Not found2Pancreatic29KRAS, FS3, SMAD430Not found2Pancreaticoma25BAP1Not foundNot found2Pancreaticoma25BAP1Not foundNot found3FGDX330Gioblastoma25BAP1Not found4PGDX21NSCLC45EGFR, EZ12, TPR, TP35, RHOH27EGFR5FGDX21NSCLC45EGFR, EZ12, TPR, TP35, RHOH00PTPRC, MF3B-RET6FGDX21NSCLC45EGFR, EZ12, TPR, TP35, RHOH130PTPRC, MF3B-RET7FGDX21NSCLC45PGDX21NSCLC46Not HART8FGDX24SCLC32PAPA2Not HART, MUNH, RUNNTT, TP33130PTPRC, MF3B-RET8FGDX24SCLC32PAPA2PAPA2Not HARS, MAPCA425COMV2AEGFR8FGDX24SCLC32PAPA2Not HARS, MAPCA426COMV2AFF3R8FGDX24SCLC32PAPA2Not HARS, MAPCA427COMV2AFF4R8FGDX24SCLC32PAPA2Not HARS, MAPCA426COMV2AFF4R8FGDX24F		PGDX368	Pancreatic	18	SMAD4, KRAS, ERBB2IP	0	0	ERBB2IP
0PGDX331Pancreatic21 $KRAS, KPC, Ps300NNN1PEdDX369Pancreatic/mat29KRAS, FS3, SMAD430Not foundNot found2Pancreatic/mat25BAP1BAP1BAP1BAP1BAP1, FEP3BAP1, FEP3BAP2CAND4, FEP3BAP1, FEP3BAP2CAND4, FEP3BAP1, FEP3BAP2CAND4, FEP3BAP1, FEP3BAP2CAND4, FEP3BAP1, FEP3BAP2CAAP2FEP3BAP1, FEP3FAP2CAAP1, FAP3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3EF3CAAP3$			Adenocarcinoma					
IncludeAdenocarcinoma29KrAS, Fo3, SMAD430Not foundIncludePancearcinoma25BAP1Carbor, FER3, AmonationaBAP1, FGFR3, AmonationaBAP1, FGFR3, AmonationaBAP2, AmonationaBAP2, AmonationaBAP2, FGFR, FAR3, FGFR4, FRAS, FGFR4, FRAS, FGFR4, FRAS, FGFR4, FGFR3, AmonationaBAP2, FGFR, FAR3, FGFR4, FRAS, FGFR4, FRAS, FGFR4, FGFR3, FGFR4, FGFR4	0	PGDX331	Pancreatic	21	KRAS, XPC, P53	0	0	XPC
1PGDX369Pancreatic29KPAS, PS3, SMD430Not found2PGDX3712Paneratic25 $BAP1$ PS3, SMD4350Not found3PGDX3712Panel carcinoma25 $BAP1$ PS3, SMD435PS471, FER7, SM111, SM21, FER7NOTCH1, FER7, SM21, FER78, SM21, FER78, SM21, FER71, SM111, SM111, SM21, SM22, FER71, SM21, SM21, FER71, SM21, FER31, SM21, FE31, SM21, SM21, FE31, SM21, SM21, FE31, SM21, SM21, FE31, FE			Adenocarcinoma					
AdenocaticionaAdenocaticionaSaltri Gerra, NOTCH1, TEFT, STK11, GIM11, STK11, GIM11, GIM11, GIM11, GIM11, GIM11, STK11, GIM11, GIM11, GIM11, GIM11, GIM11, GIM11, STK11, MUN04, GIM11, FIGS STK11, MUN04, GIM11, FIGS STK11, MUN04, GIM11, FIGS STK11, MUN04, GIM11, FIGS STK11, MUN04, GIM11, FIGS GIM12, GIM STK11, MUN04, GIM11, FIGS GIM12, GIM STK11, MUN04, GIM11, FIGS GIM12, GIM11, FIGSGIFF, FIGH11, FIGS GIM11, FIGH11, FIGS GIM114, FIGH11, FIGSGIFF, FIGH11, FIGH	-	PGDX369	Pancreatic	29	KRAS, P53, SMAD4	ო	0	Not found
2PGDX37712Renal Carcinoma25 $BAP1$ $GAP1$			Adenocarcinoma					
ADDCH1, IEH1, BEX71 GM11 ZVF688, SOC31NUCCH1, IEH1, RS2 RS2 RS2 RS2 RS2 RS2 RS2 RS2 RS2 CD0bastomaNUCCH1, IEH1, RS2 <td><math>\sim</math></td> <td>PGDX379T2</td> <td>Renal Carcinoma</td> <td>25</td> <td>BAP1</td> <td>965</td> <td>ZAP70, FGFR3,</td> <td>BAP1, FGFR3,</td>	$\sim$	PGDX379T2	Renal Carcinoma	25	BAP1	965	ZAP70, FGFR3,	BAP1, FGFR3,
3PGDX30Gioblastoma64 $MLT10, PBM1$ $ZrFeBR, SOCS1, BR2, SOCS1, BR2, BR2, SOCS1, BR2, BR2, SOCS1, BR3, SOCS1, SOC, SOC, SOC, SOC, SOC, SOC, SOC, SOC$							NUICH1, IEHI, STK11, GNA11,	NOICH1, SIK11, GNA11
3PGDX330Gioblastoma64 $MLT10$ , PBM/1 $27$ $\frac{MS2}{CDKN24, EBH71}$ EGFR4PGDX7NSCLC45EGFR, EZH2, TPR, TPS3, HHOH000EGFR, ESH25PGDX14NSCLC69ARIDAB, PIKSA6, FTPRC, TPS3,130PTPRC, KFEB-RET6PGDX140NSCLC391BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24, EBH71Fusion7PGDX24SCLC391BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24Fasion7PGDX24SCLC391BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24Fasion7PGDX24SCLC391BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24Fasion7PGDX24SCLC391BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24Fasion8PGDX24SCLC39BUB18, CYLD, EPH86, EGFR, KRAS, KEAP1,12CDKN24Fasion9PGDX24SCLC32PAPA2MOTH2MOTMotMot9PGDX35NSCLC38DLK1, JAK3NotNotNotJAK31PGDX36NSCLC38DOCH72, MM23, TNAS, SMARCA4, TPS3260NotNot1PGDX31Colon cancer12APC, EGFR, FN1, GRM3, TPS3, TSS200NotMot1PGDX32Colon cancer108APC, EGFR, KDM6A, PTS3, TSS20000GFFR, FN1, TSS2 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>ZNF668, SOCS1,</td><td></td></t<>							ZNF668, SOCS1,	
3PGDX330Glioblastoma64 <i>MLLT10, PBM1</i> 27 <i>EGFR,</i> CDK/02A, <i>EPRF1EGFR,</i> EGFR, EZH2, <i>TPR, TPS3, RHOH</i> 27 <i>EGFR,</i> CDK/02A, <i>EPRF1</i> EGFR, EGFREGFR, EZH2, <i>TPR, TPS3, RHOH</i> 000FGFR, Fusion5PGDX17NSCLC45 <i>EGFR, EZH2, TPR, TPS3, RHOH</i> 00PTPRC, <i>KIF5B-RET</i> FusionEGFR, <i>KIP3, KEAP1</i> ,1300PTPRC, <i>KIF5B-RET</i> 							IRS2	
4PGDX7NSCLC45EGFR, EZH2, TPR, TP53, RHOH00EGFR FUPRC, KF5B-RET Fusion5PGDX17NSCLC69ARIDAB, PK3R6, PTPRC, TP33,130PTPRC, KF5B-RET Fusion7NSCLC69ARIDAB, PK3R6, PTPRC, TP33,130PTPRC, KF5B-RET Fusion7PGDX140NSCLC391BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1,12CCKN2AEGFR Fusion7PGDX24SCLC32PAPPA2NUTYH, RUNX171, TP53NotNot7PGDX24SCLC32PAPPA2NOCHT2, MML3NotNot8PGDX30NSCLC38DLK1, JAK3NotNotNot9PGDX31NSCLC38DLK1, JAK3NotNotNot9PGDX33NSCLC38DLK1, JAK3NotNotNot9PGDX33SCCLC38DLK1, JAK3NotNotNot9PGDX33DOdenal cancer127CAPD11, CHL1, FANCD2, IRS1, NRAS, SIMARCA4,250Not9PGDX331Colon cancer172APC, EGFR, FV1, GRM1, TP53, TSC200061PGDX332Colon cancer108APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP5332RECOL4Ni1, INSC21PGDX310EsoPhageal cancer96PIX1, NF1, TP5332RECOL4Ni1, INSC12PGDX310EsoPhageal cancer96PIX31, NF1, TP5332RECOL4Ni1	m	PGDX330	Glioblastoma	64	WLLT10, PBRM1	27	EGFR, CDKN2A, ERRFI1	EGFR
5       PGDX17       NSCLC       69       ARIDAB, PIK3R6, PTPRC, TP33,       13       0       PTPRC, KIFSB-RET         7       TOPO2A       TOPO2A       TOPO2A       TOPO2A       STK11 Whole Gene Deletion         7       PGDX140       NSCLC       391       BUB1B, CYLL EPHB6, EGFR, KRAS, KEAP1,       12       CDKN2A       EGFR         7       PGDX24       SCLC       32       BUB1B, CYLL EPHB6, EGFR, KRAS, KEAP1,       12       CDKN2A       EGFR         7       PGDX24       SCLC       32       PAPA2       NuTVH, RUNXTT1, TP53       Not       Not       Not         8       PGDX24       SCLC       32       PAPA2       Not	4	PGDX27	NSCLC	45	EGFR, EZH2, TPR, TP53, RHOH	0	0	EGFR
TOPO2ATOPO2AEusion6 $PGDX140$ NSCLC $391$ $BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1,$ $12$ $CDKN2A$ $Eusion7PGDX24SCLC391BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1,12CDKN2AEGFR7PGDX24SCLC32PAPA2NUTYH, RUNXTT1, TPS3NotNotNot8PGDX60NSCLC32PAPA2NotTA2, NDTA, RUNXTT1, TPS3NotNotNot9PGDX3SCLC33NOCHT2, MML3NotNotNotNot0PGDX48NSCLC38DLK1, JAK3NotNotNotJAK30PGDX48Duodenal cancer127CAPD11, CHL1, FANCD2, IRS1, NPAS, SMARCA4,250NotJAK31PGDX39Colon cancer127APC, AZN12, EGFR, FN1, GRM1, TP53, TSC200002PGDX351Colon cancer108APC, AXN12, EGFR, KDM6A, PTEN, PI3KCA, TP3332AECAL4EGFR, PT1, TSC22PGDX351Colon cancer108APC, AXN12, EGFR, KDM6A, PTEN, PI3KCA, TP3332AECAL4EGFR, PI3KCA, PTEN3PGDX351EODN251EGFR, NF1, TF5332AECAL4EGFR, PI3KCA, TF33323PODN251PODPODPODPODPODPODPOD4PODPODPODPOD$	ß	PGDX17	NSCLC	69	ARID4B, PIK3R6, PTPRC, TP53,	13	0	PTPRC, KIF5B-RET
Norm       STK11       Whole Gene Deletion         PGDX140       NSCLC       391       BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1,       12       CDKN2A       EGFR         NSH6, NTRK1, NTRK3, MUTYH, RUNX1T1, TP53       Not       Not       Not       Not       Not         PGDX24       SCLC       32       PAPPA2       Not       Not       Not       Not         PGDX60       NSCLC       33       DL/1, JAK3       Not       Not       Not       Not         PGDX48       NSCLC       38       DL/1, JAK3       Not       Not       Not       JAK3         PGDX48       Duodenal cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       Not       JAK3         PGDX39       Colon cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       Not       Not       JAK3         PGDX39       Colon cancer       172       APC, EGFR, FNM6A, FIS1, NRAS, SMARCA4,       25       0       Not       Not       JAK3         PGDX397       Colon cancer       172       APC, EGFR, KDM6A, FIS1, NFAS, SMARCA4,       25       0       0       G					TOPOZA			Fusion
6       PGDX140       NSCLC       391       BUBIB. CYLD. EPHB6. EGFR, KRAS, KEAP1,       12       CDKN2A       EGFR         7       PGDX24       SCLC       32       PAPA2       NUTYH, RUNX1T1, TP53       Not       Not found         8       PGDX60       NSCLC       9       NOCHT2, MML3       Not       Not       Not found         9       PGDX3       NSCLC       9       NOCHT2, MML3       Not       Not       Not found         0       PGDX3       NSCLC       9       NOCHT2, MML3       Not       Not       Not found         0       PGDX3       NSCLC       9       NOCHT2, MML3       Not       Not       Not found         0       PGDX3       NSCLC       9       Not       Not       Not       JAK3         0       PGDX48       Duodenal cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SIMARCA4,       25       0       Not       Not       JAK3         1       PGDX39       Duodenal cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SIMARCA4,       25       0       Nacs, PIK3R1         1       PGDX39       Colon cancer <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>STK11 Whole Gene Deletion</td>								STK11 Whole Gene Deletion
7PGDX24SCLC32PAPPA2NotNotNotNot found8PGDX60NSCLC9NOCHT2, MML3600NOCTH29NSCLC38DLK1, JAK3NOCH2, MML3600NOCTH29PGDX3NSCLC38DLK1, JAK3NotNotJAK30PGDX4127CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,250NotNOCH21PGDX39Colon cancer172APC, EGFR, FN1, GRM1, TP53, TSC20066FR, FN1, TSC22PGDX31Colon cancer108APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP5332RECQL4EGFR, FN1, TSC22PGDX310Esophageal cancer96PIK3R1, NF1, TP5352CCND1NF1, PIK3R1	0	PGDX140	NSCLC	391	BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1, MSH6, NTRK1, NTRK3, MUTYH, RUNX1T1, TP53	12	CDKN2A	EGFR
B       PGDX60       NSCLC       9       NOCHT2, MML3       done       done       done         9       PGDX3       NSCLC       9       NOCHT2, MML3       6       0       NOCTH2         9       PGDX3       NSCLC       38       DLK1, JAK3       Not       Not       Not       JAK3         0       PGDX48       Duodenal cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       Not       Not       JAK3         1       PGDX39       Duodenal cancer       172       CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       NRAS, PIK3R1         1       PGDX39       Colon cancer       172       APC, EGFR, FN1, GRM1, TP53, TSC2       0       0       0       6FR, FN1, TSC2         2       PGDX317       Colon cancer       108       APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53       32       RECQL4       EGFR, FN1, TSC2         2       PGDX310       Esophageal cancer       96       PIK3R1, NF1, TP53       22       CCND1       NF1, PIK3R1		PGDX24	SCLC	32	PAPPA2	Not	Not	Not found
3       PGDX60       NSCLC       9       NOCHT2, MML3       6       0       NOCTH2         9       PGDX3       NSCLC       38       DLK1, JAK3       Not       Not       JAK3         9       PGDX4       28       DLK1, JAK3       Not       Not       Not       JAK3         1       PGDX48       Duodenal cancer       127       CAPD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       NRAS, PIK3R1         1       PGDX39       Colon cancer       172       APC, EGFR, FN1, GRM1, TP53, TSC2       0       0       0       6FR, FN1, TSC2         2       PGDX327       Colon cancer       108       APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53       32       RECQL4       EGFR, FN1, TSC2         2       PGDX310       Esophageal cancer       96       PIK3R1, NF1, TP53       52       COND1       NF1, PIK3R1						done	done	
9       PGDX3       NSCLC       38       DLK1, JAK3       Not       Not       Not       JAK3         1       A	œ	PGDX60	NSCLC	0	NOCHT2, MML3	9	0	NOCTH2
PGDX48       Duodenal cancer       127       CARD11, CHL 1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       NRAS, PIK3R1         1       PGDX39       Colon cancer       172       APC, EGFR, FN1, GRM1, TP53, TSC2       0       0       6GFR, FN1, TSC2         2       PGDX327       Colon cancer       108       APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53       32       RECQL4       EGFR, PI3KCA, PTEN         3       PGDX310       Esophageal cancer       96       PIK3R1, NF1, TF53       65       CCND1       NF1, PIK3R1	0	PGDX3	NSCLC	38	DLK1, JAK3	Not	Not	JAK3
Deg       Deg       Dudenal cancer       127       CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4,       25       0       NRAS, PIK3R1         1       PGDX39       Colon cancer       172       APC, EGFR, FN1, GRM1, TP53, TSC2       0       0       EGFR, FN1, TSC2         2       PGDX327       Colon cancer       108       APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53       32       RECQL4       EGFR, PI3KCA, PTEN         3       PGDX310       Esophageal cancer       96       PIK3R1, NF1, TF53       65       CCND1       NF1, PIK3R1						done	done	
1       PGDX39       Colon cancer       172       APC, EGFR, FN1, GRM1, TP53, TSC2       0       0       EGFR, FN1, TSC2         2       PGDX327       Colon cancer       108       APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53       32       RECQL4       EGFR, PI3KCA, PTEN         3       PGDX310       Esophageal cancer       96       PIK3R1, NF1, TF53       65       CCND1       NF1, PIK3R1	0	PGDX48	Duodenal cancer	127	CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4, TP53, PIK3R1	25	0	NRAS, PIK3R1
2 PGDX327 Colon cancer 108 APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53 32 RECQL4 EGFR, PI3KCA, PTEN 3 PGDX310 Esophageal cancer 96 PIK3R1, NF1, TP53 65 CCND1 NF1, PIK3R1	-	PGDX39	Colon cancer	172	APC, EGFR, FN1, GRM1, TP53, TSC2	0	0	EGFR, FN1, TSC2
3 PGDX310 Esophageal cancer 96 <i>PIK3R1</i> , <i>NF1</i> , <i>TP5</i> 3 65 CC <i>ND1</i> NF1, PIK3R1	N	PGDX327	Colon cancer	108	APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53	32	RECQL4	EGFR, PI3KCA, PTEN
	e	PGDX310	Esophageal cancer	96	PIK3R1, NF1, TP53	65	CCND1	NF1, PIK3R1

Garralda et al.

2480 Clin Cancer Res; 20(9) May 1, 2014 **Clinical Cancer Research** 

Figure 2. A, structural models of PI3K. Kinase domain in yellow Mutated aa in blue. Right, original protein with original aa. Left. predictive model of structural changes caused by the mutation. Severity of the mutation estimated to be high by computational analysis, B. total and activated ERK and AKT were evaluated by Western blot (WB) analysis in total protein extracts of the high-grade pancreatic neuroendocrine (PGDX7) and the glioblastoma (PGDX30) xenografted tumors. Left, total ERK and AKT proteins; right, phosphorylated forms of ERK and AKT, in the analyzed samples. GAPDH was used in all cases as loading control (P = phospho). C and D, representative tumor growth curve of Avatar PGDX7 treated with the studied agents. PI3i: 20 mg/kg per os; everyday, Monday-Friday (M-F), for 28 days. MEKi: 4mg/kg per os; everyday, M-F, for 28 days. PI3Ki + MEKi: 20 mg/kg per os + 4 mg/kg per os;everyday, M-F, for 28 days. PI3Ki+Gemcitabine: 20 mg/kg per os; everyday, M-F, for 28 days -100 mg/kg i.p.; twice a week for 28 days, E and F, representative tumor growth curve of Avatar PGDX30 treated with the studied agents. OSI774 (erlotinib): 50 mg/kg i.p.; daily for 28 days. Rapamycin: 4 mg/ kg per os: daily, for 10 days, FTS: 100 mg/kg per os; daily, for 28 days. OSI774 (erlotinib) rapamycin: 50 mg/kg i.p.; daily, for 28 days + 4 mg/kg per os; daily for 28 days. PI3Ki: 20 mg/kg per os; daily M-F, for 28 days. MEKi: 4 mg/ kg per os; daily M-F, for 28 days. PI3Ki + MEKi: 20 mg/kg per os; daily M-F + 4 mg/kg per os; daily M-F for 28 days.



in patient #16 with non-small cell lung cancer (NSCLC). Genomic analysis showed a mutation in *EGFR* not described previously (p.A1158V). A battery of treatments was tested in the Avatar, including treatment with erlotinib; however, other agents such as everolimus and nab-paclitaxel were more effective. Based on these data, the patient was treated with nab-paclitaxel and everolimus achieving a partial response.

Furthermore, Avatar models were used to test empirically potential active drugs for individualized patient treatment when there were no druggable alterations identified. This is well illustrated in patient #17 diagnosed of advanced smallcell lung cancer (SCLC). NGS revealed 32 mutations, none were actionable. She received two consecutive personalized treatments based solely on her personal Avatar results obtaining a favorable outcome both times (Table 3).

#### **Clinical outcome**

A total of 13 patients have received a treatment based on the genomic and/or Avatar model data (Table 3), including 5 patients who received more than one sequential tailored treatment. Six patients achieved partial remissions and 7 patients are currently on treatment with at least disease stabilization. The Avatar proved to be useful guiding a successful therapy in 5 patients. In 4 patients, the treatment was based exclusively on Avatar mouse models (#15, 16, 17, and 20), receiving multiple sequential guided treatments. On the whole, 13 treatments were Avatar directed, and in 11

www.aacrjournals.org

1     Neuroendocrine     CREB3L3 mutation     No engratiment     Sandostatin + metformin turnor       2     Glioblastoma     NF1 mutation     Rapamycine +     Everolinus + enfotinib + b endotinib       3     High grade     P/3KCA, DDR2     MEK inh +     Dasatinib       3     High grade     P/3KCA, DDR2     MEK inh +     Dasatinib       5     Uveal     RM11 mutations     P/3K inh     Dasatinib       6     Uveal     GNA11 mutation     No engratiment     1st: Protein kinase C inhib       7     Uveal     GNA11 mutation     No engratiment     1st: Protein kinase C inhib       10     PDAC     XPC mutation     Not performed     Mitomycin C + inhotecan       13     Glioblastoma     EGFR amplification     Not performed     Mitomycin C + inhotecan       13     Glioblastoma     EGFR mutation     Not performed     Mitomycin C + inhotecan       14     NSCLC     PTPRC mutation     Not performed     Mitomycin C + inhotecan       14     NSCLC     PTPRC mutation     Not performed     Mitomycin C + inhotecan       15     NSCLC     PTPRC mutation     Not performed     Mitomycin C + inhotecan	SD Complete metabolic response by PET pevacizumab PD PD pD iteration and the second se		
Lumor   Lumor     3   High grade   PI3KCA, DDR2   MEK inh +   Everolimus + ertotinib     3   High grade   PI3KCA, DDR2   MEK inh +   Dasatinib     3   Pigh grade   PI3KCA, DDR2   MEK inh +   Dasatinib     5   Uveal   GMA11 mutations   No   Everolimus + ertotinib     6   Uveal   GNA11 mutation   No engraftment   1st: Protein kinase C inhib     10   PDAC   XPC mutation   No engraftment   1st: Protein kinase C inhib     11   PDAC   XPC mutation   No engraftment   1st: Innotecan     12   Renal   BAP1 mutation   Not performed   Mitomycin C     13   Glioblastoma   EGFR mutation   Not performed   Mitomycin C     14   NSCLC   PTPRC mutation   Not performed   Mitomycin C     15   NSCLC   PTPRC mutation   Not performed   Mitomycin C     16   NSCLC   PTPRC mutation   Not performed   Mitomycin C     16   NSCLC   PTPRC mutation   Not performed   Mitomycin C     16   NSCLC   PTPRC mutation   No engraftment   1st. Irinotecan + performed     16   NSCLC   EGFR   -linin tecan   3rd. Sunitinib <	response by PET bevacizumab PD PD vitor SD	9 B	On treatment
3   High grade   P/3KCA, DDR2   MEK inh +   Dasatinib     pancreatic   mutations   P/3KCA, DDR2   MEK inh +   Dasatinib     pancreatic   mutations   P/3K inh   Dasatinib     tumor   GNA11 mutation   No engraftment   1st: Protein kinase C inhib     5   Uveal   GNA11 mutation   No engraftment   1st: Protein kinase C inhib     6   Uveal   GNA11 mutation   No engraftment   1st: Protein kinase C inhib     10   PDAC   XPC mutation   Not performed   Mitomycin C     12   Renal   BAP7 mutation   Not performed   Mitomycin C     13   Glioblastoma   EGFR mutation   Not performed   Mitomycin C     14   NSCLC   EGFR mutation   Not performed   Mitomycin C     15   NSCLC   FGFR mutation   Not performed   Erforinib     16   NSCLC   FGFR mutation   Not performed   Erforinib     16   NSCLC   EGFR   Mab-paclitaxel + even     16   NSCLC   EGFR   -Cisplatin +     16   NSCLC   EGFR   -Cisplatin +     16   NSCLC   EGFR   -Cisplatin +     17   SCLC   No target   -Ininotecan <td>PD bitor SD</td> <td>_ ۳</td> <td>Dead</td>	PD bitor SD	_ ۳	Dead
1   Incorrection     tumor   1st: Protein kinase C inhib     tumor   1st: Protein kinase C inhib     tumor   1st: Protein kinase C inhib     nelanoma   2nd: Carboplatin + pacita     10   PDAC   XPC mutation     12   Renal   BAP1 mutation     13   Glioblastoma   EGFR mutation     14   NSCLC   EGFR mutation     15   NSCLC   PTPRC mutation     16   NSCLC   PTPRC mutation     16   NSCLC   Foltinib     17   SCLC   Protein kinase C inhib     16   NSCLC   Carboplatin + pacificate     17   SCLC   Partition     18   Mitomycin C + irinotecan     19   NSCLC   Partition     10   PDAC   Partition     11   NSCLC   Partition     12   Renal   BAP1     13   Glioblastoma   EGFR     14   NSCLC   Partition     15   NSCLC   Partition     16   NSCLC   Partition     16   NSCLC   EGFR     17   SCLC   Partition     17   SCLC   No target     17   SCLC	oitor SD		Dead
10     PDAC     XPC mutation     Not performed     Pi3k inhibitor       12     Renal     BAP1 mutation     Not performed     Mitomycin C       13     Glioblastoma     EGFR amplification     Not performed     Mitomycin C + irinotecan       13     Glioblastoma     EGFR amplification     Not performed     Mitomycin C + irinotecan       14     NSCLC     EGFR mutation     Not performed     Mitomycin C + irinotecan       15     NSCLC     EGFR mutation     Not performed     Mitomycin C + irinotecan       16     NSCLC     FGFR mutation     Not performed     Thinotecan + pemetrex       16     NSCLC     FGFR     -linotecan +     1st: linotecan + pemetrex       16     NSCLC     FGFR     -linotecan +     1st: linotecan + pemetrex       16     NSCLC     FGFR     -linotecan +     1st: linotecan + pemetrex       16     NSCLC     EGFR     -linotecan +     1st: linotecan + pemetrex       16     NSCLC     EGFR     -linotecan +     2nd: Nab-paclitaxel + evel       16     NSCLC     EGFR     -linotecan +     2nd: Nab-paclitaxel + evel       17     SCLC     No ta		4	Other treatment
0     PDAC     XPC mutation     Not performed     Mitomycin C       2     Renal     BAP1 mutation     Not performed     Mitomycin C + irinotecan       3     Glioblastoma     EGFR amplification     Not performed     Mitomycin C + irinotecan       14     NSCLC     EGFR mutation     Not performed     Erlotinib       15     NSCLC     EGFR mutation     No engraftment     Erlotinib       16     NSCLC     PTPRC mutation.     -linotecan +     1st: lrinotecan + pemetrex       16     NSCLC     EGFR     -linotecan +     3rd: Sunitinib       16     NSCLC     EGFR     -linotecan +     2nd: Nab-paclitaxel + evel       16     NSCLC     EGFR     -cisplatin +     1st: Cisplatin + gemcitabin       17     SCLC     No target     -finotecan     1st: Irinotecan       17     SCLC     No target     -finotecan     1st: Irinotecan	txel +		
2     Renal     BAP1 mutation     Not performed     Mitomycin C + irinotecan       3     Glioblastoma     EGFR amplification     Not performed     Erlotinib       14     NSCLC     EGFR mutation     Not performed     Erlotinib       15     NSCLC     FGFR mutation     No engraftment     Erlotinib       15     NSCLC     PTPRC mutation.     -Irinotecan +     1st: Irinotecan + permetrex       16     NSCLC     PTP11 Whole Gene     -Nab-paclitaxel +     2nd: Nab-paclitaxel + evel       16     NSCLC     EGFR     -Cisplatin +     1st: Cisplatin + gencitabin       16     NSCLC     EGFR     -Cisplatin +     1st: Cisplatin + gencitabin       17     SCLC     No target     -Irinotecan     1st: Irinotecan       17     SCLC     No target     -Irinotecan     1st: Irinotecan	PD	3	Dead
[3   Glioblastoma   EGFR amplification   Not performed   Erlotinib     [4   NSCLC   EGFR mutation   No engraftment   Erlotinib     [5   NSCLC   PTPRC mutation.   Irinotecan +   1st: Irinotecan + permetrex     [6   NSCLC   PTPRC mutation.   Permetrexed +   2nd: Nab-paclitaxel + evel     [6   NSCLC   EGFR   -Nab-paclitaxel +   3rd: Sunitinib     [6   NSCLC   EGFR   -Cisplatin +   1st: Cisplatin + gemcitabin     [6   NSCLC   EGFR   Cisplatin +   1st: Cisplatin + gemcitabin     [6   NSCLC   EGFR   Cisplatin +   1st: Cisplatin + gemcitabin     [7   SCLC   No target   Irinotecan   1st: Irinotecan	SD	3+	On treatmer
4     NSCLC     EGFR mutation     No engraftment     Erlotinib       5     NSCLC     EGFR mutation.     -Irinotecan +     1st: Irinotecan + pemetrex       KIF5B-RET Fusion     pemetrexed +     1st: Irinotecan + pemetrex       KIF5B-RET Fusion     pemetrexed +     1st: Irinotecan + pemetrex       KIF5B-RET Fusion     pemetrexed +     1st: Irinotecan + pemetrex       NSCLC     EGFR     -Nab-paclitaxel +     2nd: Nab-paclitaxel + evel       0     NSCLC     EGFR     -Cisplatin +     1st: Cisplatin + gemcitabin       0     NSCLC     EGFR     -Cisplatin +     1st: Cisplatin + gemcitabin       1     SCLC     No target     -Nab-paclitaxel     2nd: Nab-paclitaxel + evel       7     SCLC     No target     -Irinotecan     1st: Irinotecan	SD	3+	On treatmer
5     NSCLC     PTPRC mutation.     -Irinotecan +     1st: Irinotecan + pemetrax       KIF5B-RET Fusion     pemetraxed +     1st: Irinotecan + pemetrax       KIF5B-RET Fusion     pemetraxed +     1st: Irinotecan + pemetrax       KIF5B-RET Fusion     pemetraxed +     2nd: Nab-paclitaxel + evel       STK11 Whole Gene     -Nab-paclitaxel +     2nd: Nab-paclitaxel + evel       Deletion     everolimus     3rd: Sunitinib       Deletion     everolimus     3rd: Sunitinib       0     NSCLC     EGFR     -Cisplatin +       1st: Cisplatin +     1st: Cisplatin + gemcitabin       1st: Cisplatin +     2nd: Nab-paclitaxel + evel       1st: Intotecan     2nd: Nab-paclitaxel + evel       1     SCLC     No target     -Ininotecan       1     SCLC     No target     -Ininotecan       -Nab-paclitaxel     2nd: Nab-paclitaxel     2nd: Nab-paclitaxel	PR	24+ (	On treatmer
KIF5B-RET Fusion     pemetrexed +       KIF5B-RET Fusion     bevacizumab       STK11     Whole Gene     -Nab-paclitaxel +       STK11     Whole Gene     -Nab-paclitaxel +       Deletion     everolimus     3rd: Sunitinib       G     NSCLC     EGFR     -Cisplatin +       Packitabile     -Cisplatin +     1st: Cisplatin + gemcitabil       gemcitabile     -Cisplatine     2nd: Nab-paclitaxel + evel       7     SCLC     No target     -Ininotecan       7     SCLC     No target     -Ininotecan       -Nab-paclitaxel     2nd: Nab-paclitaxel     2nd: Nab-paclitaxel	xed + bevacizumab 1st: CR	1st: 13 (	On treatmer
STK11 Whole Gene   -Nab-paclitaxel +   2nd: Nab-paclitaxel + evel     Deletion   everolimus   3rd: Sunitinib     Deletion   everolimus   3rd: Sunitinib     0   NSCLC   EGFR   -Cisplatin +     1st: Cisplatin +   1st: Cisplatin + gemcitabine     1st: Cisplatin +   1st: Cisplatin + gemcitabine     1st: Cisplatin +   1st: Cisplatin + gemcitabine     1st: Introduct   2nd: Nab-paclitaxel + evel     1st: Irinotecan   1st: Irinotecan     1st: Istinotecan   2nd: Nab-paclitaxel			
Deletion   everolimus   3rd: Sunitinib     6   NSCLC   EGFR   -Cisplatin +   1st: Cisplatin + gemcitabin     9   9   9   1st: Cisplatin + gemcitabin     -Nab-paclitaxel   2nd: Nab-paclitaxel + evel     -Feverolimus   1st: Irinotecan     7   SCLC   No target     -Nab-paclitaxel   2nd: Nab-paclitaxel + evel	srolimus 2nd: PR	2nd: 4	
I6   NSCLC   EGFR   -Cisplatin +   1st: Cisplatin + gemcitabin     gemcitabine   gemcitabine   2nd: Nab-paclitaxel + evel     -Nab-paclitaxel   2nd: Nab-paclitaxel + evel     -Everolimus   1st: Irinotecan     17   SCLC   No target     -Nab-paclitaxel   2nd: Nab-paclitaxel + evel	3rd: SD	3rd: 2+	
gemcitabine -Nab-paclitaxel 2nd: Nab-paclitaxel + ever -Everolimus -Irinotecan -Nab-paclitaxel 2nd: Nab-paclitaxel	ne 1st: PR	1st: 6 (	On treatmer
7 SCLC No target -Ininotecan 1st: Irinotecan -Ininotecan -Nab-paclitaxel 2nd: Nab-paclitaxel	stolimus 2nd: PR	2nd: 3+	
-Nab-paclitaxel 2nd: Nab-paclitaxel	1st: PR	1st: 6	Dead
	2nd: SD	2nd: 4	
20 Duodenal NRAS and PIK3R1 -Gemcitabine + 1st: Irinotecan + cetuxima	ab 1st: PR	1st: 3 I	Dead
-Eribuline 2nd: Eribuline	2nd: PD	2nd: 1	
-Irinotecan + 3rd: Gemcitabine	3rd: PD	3rd: 1	
22 Colorectal EGFR and PIK3CA Irinotecan + Irinotecan + panitumumab	PR	2+ (	On treatmer

**2482** Clin Cancer Res; 20(9) May 1, 2014

**Clinical Cancer Research** 

the Avatar response mimicked the patient response, predicting 2 progressive disease, 1 complete response, 6 partial response, and 2 stable disease (Table 3). In 3 patients, no potential targetable alteration was found, including two pancreatic adenocarcinoma (PDAC) with a *KRAS* mutation and no animal model and the SCLC described above which received Avatar-guided treatment.

#### Discussion

This report summarizes our experience of personalizing treatment of advanced cancer patients by integrating data obtained by NGS techniques and Avatar mouse models developed from the patient's own tumor. This work is one of the first experiences to apply these technological advances to patient care and shows the feasibility of the approach. At this time, 57% patients have received a personalized therapy and out of them 77% have experienced a clinical benefit (stable disease or partial response) with the tailored treatment. Several aspects are worth discussing.

All tumor samples profiled contained biologically or clinically potentially meaningful genomic alterations, including several that might predict sensitivity or resistance to targeted agents. Thus, exome-sequencing analysis provides a comprehensive approach for the detection of multiple categories of actionable genetic alterations. However, the use of this information is complex because of the high number of somatic alterations encountered and the lack of biologic testing or data for most identified alterations. Functional validation is the gold standard for assessing the mutation significance and in this sense, personalized xenografts developed in mice from patients' tumor tissues, such as Avatar models, offer a tool to test and validate the hypothesis generated by the genetic analysis (18, 19). This is best illustrated in patient #3 in whom the exome analysis of his tumor showed a plausibly actionable alteration in the PIK3CA gene. Bioinformatic tools predicted the relevance of the mutation to be high; however, PI3K inhibitors failed to offer activity in the animal model.

It is becoming clear that predicting treatment response to known oncogenes is complex and requires detailed information of how different genetic backgrounds function and about how the neoplastic stroma will contribute to drug response. The redundancies of the proliferative signaling pathways may underlay the lack of response in some patients whose tumors express oncogenic targets, and are consequently treated with matched targeted drugs but fail to obtain a therapeutic benefit (20). For example, in patient #3 the activation of the MAPK pathway due to the amplification of GNG11 could explain the failure of PI3K inhibitors and highlights the importance in obtaining CNVs in addition to assessing gene mutations. To fine-tune therapies to be efficacious in each individual, not only common driver mutations will have to be analyzed but we will also need to develop a deeper understanding of the individual diversity in the biology of cancer among patients with a priori similar tumors. A systems approach will be necessary to determine if analyzing alterations in signaling pathways, as opposed to directly targeting mutated genes, can prove to be more

useful. In our cases, for example, the DNA repair pathway alterations found in patients #10 and #12 could be targeted mechanistically using drugs that take advantage of these altered DNA repair mechanisms.

Avatar models may help resolve some of the above mentioned issues as they can help channel the genomic analysis results into appropriate empiric testing. As seen in our results, they are an accurate *in vivo* platform to test proposed treatment strategies, showing an existing remarkable correlation between drug activity in the Avatar and clinical outcome in the patients, in terms of both drug resistance and sensitivity. Moreover, in most cases when genomic analysis provided little insight or targeting pathways failed, more conventional drugs and combinations were appropriately selected only because of the Avatar model.

There are different technologies that allow us to interrogate the genomic profile of a tumor, such as sequencing only a target panel of genes, which could facilitate the interpretation and analysis of the results. However, the advantages of sequencing exome rather than selected targets are several, including the possible identification of a larger number of druggable mutated genes and discovering possible new genes involved in the tumorigenesis that allow a more comprehensive analysis. In addition, the costs of exome sequencing are continuing to diminish and the results can be obtained in a relatively short time.

There are limitations with this combined approach that continue to challenge its broad clinical application. First, important technical issues regarding tumor profiling remain to be solved to obtain readily interpretable results, for example: choosing the most appropriate technique (target sequencing vs. exome sequencing vs. whole-genome sequencing; ref. 21), observed tumor heterogeneity (22), subclonal evolution (23), or selecting primary tumor versus metastatic tumors (24). Second, the generation of a personalized xenograft model has limitations, requiring large amounts of fresh tumor material and intense resources. Engraftment failure is still an issue that can be improved.

The development and propagation of the Avatar model and drug testing takes 4 to 6 months and, in addition, the failure rate in tumorgraft establishment is also a drawback. Finally, there are also practical issues in the everyday clinical setting that have to be considered. Examples are patient #3 in which the optimal tailored treatment (the combined PI3K and MEK inhibitors) could not be given or patient #8 having a melanoma with an *NRAS* mutation but not meeting eligibility criteria to participate in a clinical study. Difficult access to the drug or combination treatment can be a major drawback.

In summary, here we describe our experience using a new approach to determine the optimal treatment for an individual patient with cancer. The sample size remains at the time too small and heterogeneous to conclude if this approach will be better than the standard-of-care approach to select therapy. However, the work represents an important advance showing that the analysis of somatic genetic alterations plus the use of the patient's tumor growing in

www.aacrjournals.org

nude mice can be performed in the clinical setting and can guide to specific treatments in a significant fraction of patients. The detection of actionable tumor-specific genomic alterations in the clinical setting is at the time feasible; however, predicting treatment response to known oncogenes is still complex. Bench testing of candidate treatments in patient-derived xenografts correlates with clinical response and may help to select treatment in some of the patients with no actionable mutations, helping in the challenge of linking confirmed mutations to biologic function and ultimately to clinical response and utility. Despite limitations in efficiency, speed, and cost; our current data suggest that further studies applying the Avatar-Exome integrating approach might yield promising results to the arising field of personalized cancer medicine.

#### **Disclosure of Potential Conflicts of Interest**

L.A. Diaz is an officer and board member for and has ownership interest (including patents) in Personal Genome Diagnostics; has received speakers bureau honoraria from Illumina; and is a consultant/advisory board member for Amgen. V.E. Velculescu is employed on the board of directors of, is CSO for, and has ownership interest (including patents) in Personal Genome Diagnostics. D. Sidransky is a chairman of, has ownership interest (including patents) in, and is a consultant/advisory board member for Champions Oncology. M. Hidalgo has ownership interest (including patents) in Champions Oncology. No potential conflicts of interest were disclosed by the other authors.

#### References

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
- Corless CL. Medicine. Personalized cancer diagnostics. Science 2011;334:1217–8.
- Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol 2010;28:5219–28.
- Baker M. Functional genomics: the changes that count. Nature 2012:482:257.
- Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011;331:1553–8.
- Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012;18: 619–24.
- Valencia A, Hidalgo M. Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. Genome Med 2012; 4:61.
- Brunham LR, Hayden MR. Medicine. Whole-genome sequencing: the new standard of care? Science 2012;336:1112–3.
- Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28:4877–83.
- Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012;148:409–20.
- Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 2012;18:5160–2.
- Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311–6.
- Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, lacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12: 4652–61.

#### Authors' Contributions

Conception and design: E. Bruckheimer, V.E. Velculescu, D. Sidransky, M. Hidalgo

Development of methodology: K. Paz, P.P. López-Casas, F. López-Rios, F. Sarno, V.E. Velculescu, M. Hidalgo

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Garralda, P.P. López-Casas, A. Katz, F. López-Rios, F. Sarno, D. Vasquez, E. Bruckheimer, A. Calles, D. Sidransky, M. Hidalgo

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Garralda, K. Paz, P.P. López-Casas, S. Jones, F. López-Rios, F. Al-Shahrour, S.V. Angiuoli, L.A. Diaz, V.E. Velculescu, D. Sidransky, M. Hidalgo

Writing, review, and/or revision of the manuscript: E. Garralda, K. Paz, P. P. López-Casas, S. Jones, F. López-Rios, A. Calles, L.A. Diaz, V.E. Velculescu, M. Hidalgo

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E. Garralda, L.M. Kann, F. Sarno, D. Vasquez, E. Bruckheimer, A. Calles

Study supervision: K. Paz, V.E. Velculescu, A. Valencia

#### Acknowledgments

The authors thank C. McCord, M. Shukla, Carlos Gómez-Martin, Mónica Musteanu, and Raquel Martinez for their assistance.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 5, 2013; revised February 9, 2014; accepted February 10, 2014; published OnlineFirst March 14, 2014.

- Hossain MN, Sakemura R, Fujii M, Ayusawa D. G-protein gamma subunit GNG11 strongly regulates cellular senescence. Biochem Biophys Res Commun 2006;351:645–50.
- Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78–89.
- Yalon M, Rood B, MacDonald TJ, McCowage G, Kane R, Constantini S, et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 2013;60:71–6.
- Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res 2013;19: 450–61.
- Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 2012;30:e45–8.
- Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10:3–8.
- Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010;16:974–5.
- Dong H, Wang S. Exploring the cancer genome in the era of nextgeneration sequencing. Front Med 2012;6:48–55.
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–92.
- Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481:306–13.
- 24. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:1020–6.

2484 Clin Cancer Res; 20(9) May 1, 2014

#### **Clinical Cancer Research**



## **Clinical Cancer Research**

# Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Elena Garralda, Keren Paz, Pedro P. López-Casas, et al.

Clin Cancer Res 2014;20:2476-2484. Published OnlineFirst March 14, 2014.



Cited articles	This article cites 24 articles, 13 of which you can access for free at: http://clincancerres.aacrjournals.org/content/20/9/2476.full#ref-list-1
Citing articles	This article has been cited by 15 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/20/9/2476.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/20/9/2476. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.